Skip Navigation

British Medical Bulletin 2009 89(1):1-6; doi:10.1093/bmb/ldp008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in BMB
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vetter, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vetter, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Editor's Choice

Norman Vetter

The first 150 words of the full text of this article appear below.

Another year and for this first quarter the British Medical Bulletin has another wide variety of reviews in topics that are new or of special relevance to modern medical practice.

The first review, on ethics, is about ‘Terminal illness and access to phase 1 experimental agents, surgeries and devices’ (page 7) by Schuklenk and Lowry from Kingston in Ontario, Canada.

They make the point that the advent of AIDS identified a group of patients unwilling to accept crucial aspects of the methodological standards for clinical research investigating phase 1 drugs, surgery or devices. They argued against placebo controls in trials that depended on the terminal status of patient volunteers, and led to a renewed discussion of the ethics of denying patients with catastrophic illnesses access to last-chance experimental drugs, surgeries or devices. At present, the positions of those arguing for or against free access to experimental drugs for terminally . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in BMB:

Terminal illness and access to Phase 1 experimental agents, surgeries and devices: reviewing the ethical arguments
Udo Schüklenk and Christopher Lowry
BMB 2009 89: 7-22. [Abstract] [Full Text]  

The potential role and application of PARP inhibitors in cancer treatment
Anthony J. Chalmers
BMB 2009 89: 23-40. [Abstract] [Full Text]  

Recognition and treatment of Asperger syndrome in the community
Digby Tantam and Sobhi Girgis
BMB 2009 89: 41-62. [Abstract] [Full Text]  

Cardiac radionuclide imaging in stable coronary artery disease and acute coronary syndromes
James Stirrup, Kshama Wechalekar, Annelies Maenhout, and Constantinos Anagnostopoulos
BMB 2009 89: 63-78. [Abstract] [Full Text]  

Advanced life support update
Natalie Husselbee, Robin P. Davies, and Gavin D. Perkins
BMB 2009 89: 79-91. [Abstract] [Full Text]  

Recent advances in the microbiology of respiratory tract infection in cystic fibrosis
Juliet Foweraker
BMB 2009 89: 93-110. [Abstract] [Full Text]  

History and evolution in total ankle arthroplasty
Nikolaos E. Gougoulias, Anil Khanna, and Nicola Maffulli
BMB 2009 89: 111-151. [Abstract] [Full Text]  

Hepatitis C virus: the growing challenge
Brian J. Thomson
BMB 2009 89: 153-167. [Abstract] [Full Text]  

The effects of LIPUS on soft-tissue healing: a review of literature
Anil Khanna, Richard T. C. Nelmes, Nikolaos Gougoulias, Nicola Maffulli, and Jim Gray
BMB 2009 89: 169-182. [Abstract] [Full Text]  

Aicardi–Goutières syndrome
S. Orcesi, R. La Piana, and E. Fazzi
BMB 2009 89: 183-201. [Abstract] [Full Text]